A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R.sub.1 is a C.sub.2-10 alkyl, C.sub.2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R.sub.1 is a C.sub.2-10 alkyl, C.sub.2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

The present invention relates to the field of chemical processes and, more particularly, it concerns valuable new chemical intermediates of formula (IV) for producing perfuming ingredients.

The present invention relates to the field of chemical processes and, more particularly, it concerns valuable new chemical intermediates of formula (IV) for producing perfuming ingredients.

The present invention discloses the application of cyathane diterpenoids in preparation of drugs for treating neuroinflammation. Seven cyathane diterpenoids 1-7 can significantly prevent LPS-induced BV-2 microglia from producing NO. The most active compound as 6 can reverse M1/M2 polarization of the microglia. 6 inhibits the pro-inflammatory proteins including iNOS and COX-2 through MAPK/NF-κB signaling pathways and promote the anti-inflammatory factors including IL-10 and ARG-1. An application prospect of the anti-inflammatory cyathane diterpenoids in the treatment of the neurodegenerative diseases is achieved.

The present invention discloses the application of cyathane diterpenoids in preparation of drugs for treating neuroinflammation. Seven cyathane diterpenoids 1-7 can significantly prevent LPS-induced BV-2 microglia from producing NO. The most active compound as 6 can reverse M1/M2 polarization of the microglia. 6 inhibits the pro-inflammatory proteins including iNOS and COX-2 through MAPK/NF-κB signaling pathways and promote the anti-inflammatory factors including IL-10 and ARG-1. An application prospect of the anti-inflammatory cyathane diterpenoids in the treatment of the neurodegenerative diseases is achieved.

The present invention relates to a transition metal complex having a PNNP4 ligand, which is easy to manufacture and handle and is relatively inexpensively available, and a method for manufacturing the same, as well as a method using this transition metal complex as a catalyst for hydrogenation reduction of ketones, esters and amides to manufacture corresponding alcohols, aldehydes, hemiacetals and hemiaminals, a method using this transition metal complex as a catalyst for oxidation of alcohols, hemiacetals and hemiaminals to manufacture corresponding carbonyl compounds, and a method using this transition metal complex as a catalyst for dehydrogenation condensation between alcohols and amines to manufacture alkylamines.

The present invention relates to a transition metal complex having a PNNP4 ligand, which is easy to manufacture and handle and is relatively inexpensively available, and a method for manufacturing the same, as well as a method using this transition metal complex as a catalyst for hydrogenation reduction of ketones, esters and amides to manufacture corresponding alcohols, aldehydes, hemiacetals and hemiaminals, a method using this transition metal complex as a catalyst for oxidation of alcohols, hemiacetals and hemiaminals to manufacture corresponding carbonyl compounds, and a method using this transition metal complex as a catalyst for dehydrogenation condensation between alcohols and amines to manufacture alkylamines.

The present disclosure relates generally to various forms and compositions useful as beta adrenergic agonists and uses of the same in the treatment of diseases associated with an adrenergic receptor. In one aspect, the disclosure provides a crystalline solid form of Compound 1: selected from Form A and Form B and salt forms thereof.

##STR00001##

The present disclosure relates generally to various forms and compositions useful as beta adrenergic agonists and uses of the same in the treatment of diseases associated with an adrenergic receptor. In one aspect, the disclosure provides a crystalline solid form of Compound 1: selected from Form A and Form B and salt forms thereof.

##STR00001##